Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy

被引:71
|
作者
Zile, Michael R. [1 ,2 ]
Abraham, William T. [3 ]
Weaver, Fred A. [4 ]
Butter, Christian [5 ]
Ducharme, Anique [6 ]
Halbach, Marcel [7 ]
Klug, Didier [8 ]
Lovett, Eric G. [9 ]
Mueller-Ehmsen, Jochen [10 ]
Schafer, Jill E. [11 ]
Senni, Michele [12 ]
Swarup, Vijay [13 ]
Wachter, Rolf [14 ,15 ]
Little, William C. [16 ]
机构
[1] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA
[2] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA
[3] Ohio State Univ, Div Cardiovasc Med, Columbus, OH 43210 USA
[4] Univ So Calif, Keck Sch Med, Div Vasc Surg & Endovasc Therapy, Los Angeles, CA 90033 USA
[5] Immanuel Heart Ctr Bernau, Med Sch Brandenburg, Dept Cardiol, Bernau, Germany
[6] Univ Montreal, Montreal Heart Inst, Montreal, PQ H3C 3J7, Canada
[7] Univ Hosp Cologne, Dept Internal Med 3, Cologne, Germany
[8] Univ Hosp, Dept Cardiol A, Lille, France
[9] CVRx Inc, Dept Res, Minneapolis, MN USA
[10] Asklepios Klin Altona, Dept Med, Hamburg, Germany
[11] NAMSA Inc, Dept Stat, Minneapolis, MN USA
[12] Osped Papa Giovanni XXIII, Cardiovasc Dept, Bergamo, Italy
[13] Arizona Heart Hosp, Dept Electrophysiol, Phoenix, AZ USA
[14] Univ Med Gottingen, Clin Cardiol & Pneumol, Gottingen, Germany
[15] German Cardiovasc Res Ctr DZHK, Gottingen, Germany
[16] Univ Mississippi, Div Cardiovasc, Med Ctr, Jackson, MS 39216 USA
关键词
Baroreflex; Heart failure; Resynchronization; Autonomic nervous system; Randomized controlled trial; INHIBITION; SYSTEM;
D O I
10.1002/ejhf.299
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsIncreased sympathetic and decreased parasympathetic activity contribute to heart failure (HF) symptoms and disease progression. Carotid baroreceptor stimulation (baroreflex activation therapy, BAT) results in centrally mediated reduction of sympathetic and increase in parasympathetic activity. Because patients treated with cardiac resynchronization therapy (CRT) may have less sympathetic/parasympathetic imbalance, we hypothesized that there would be differences in the response to BAT in patients with CRT vs. those without CRT. Methods and resultsNew York Heart Association (NYHA) Class III patients with an ejection fraction (EF) 35% were randomized (1 : 1) to ongoing guideline-directed medical and device therapy (GDMT, control) or ongoing GDMT plus BAT. Safety endpoint was system-/procedure-related major adverse neurological and cardiovascular events (MANCE). Efficacy endpoints were Minnesota Living with Heart Failure Quality of Life (QoL), 6-min hall walk distance (6MHWD), N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and HF hospitalization rate. In this sample, 146 patients were randomized (70 control; 76 BAT) and were 140 activated (45 with CRT and 95 without CRT). MANCE-free rate at 6 months was 100% in CRT and 96% in no-CRT group. At 6 months, in the no-CRT group, QoL score, 6MHWD, LVEF, NT-proBNP and HF hospitalizations were significantly improved in BAT patients compared with controls. Changes in efficacy endpoints in the CRT group favoured BAT; however, the improvements were less than in the no-CRT group and were not statistically different from control. ConclusionsBAT is safe and significantly improved QoL, exercise capacity, NTpro-BNP, EF, and rate of HF hospitalizations in GDMT-treated NYHA Class III HF patients. These effects were most pronounced in patients not treated with CRT.
引用
收藏
页码:1066 / 1074
页数:9
相关论文
共 50 条
  • [11] Evaluation of potential underuse of cardiac resynchronization therapy for heart failure with reduced ejection fraction
    Takano, Makoto
    Nakayama, Yui
    Matsuda, Hisao
    Harada, Tomoo
    Akashi, Yoshihiro J.
    JOURNAL OF ARRHYTHMIA, 2021, 37 (06) : 1532 - 1536
  • [12] Baroreceptor activation therapy in heart failure with reduced ejection fraction
    Hohmann, Stephan
    Bauersachs, Johann
    Veltmann, Christian
    KARDIOLOGE, 2020, 14 (06): : 551 - 560
  • [13] Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials
    Coats, Andrew J. S.
    Abraham, William T.
    Zile, Michael R.
    Lindenfeld, Joann A.
    Weaver, Fred A.
    Fudim, Marat
    Bauersachs, Johann
    Duval, Sue
    Galle, Elizabeth
    Zannad, Faiez
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (09) : 1665 - 1673
  • [14] Baroreflex Activation Therapy in Heart Failure With Reduced Ejection Fraction: Available Data and Future Perspective
    Halbach M.
    Fritz T.
    Madershahian N.
    Pfister R.
    Reuter H.
    Current Heart Failure Reports, 2016, 13 (2) : 71 - 76
  • [15] Cardiopulmonary function during exercise in heart failure with reduced ejection fraction following baroreflex activation therapy
    Nottebohm, Pia, I
    Dumitrescu, Daniel
    Hamacher, Stefanie
    Hohmann, Christopher
    Madershahian, Navid
    Baldus, Stephan
    Reuter, Hannes
    Halbach, Marcel
    THERAPEUTIC ADVANCES IN CARDIOVASCULAR DISEASE, 2022, 16
  • [16] Baroreflex activation therapy. A novel interventional approach to treat heart failure with reduced ejection fraction
    Halbach, M.
    Fritz, T.
    Madershahia, N.
    Pfister, R.
    Reuter, H.
    HERZ, 2015, 40 (07) : 959 - 965
  • [17] Do Poor Responders to Cardiac Resynchronization Therapy also Poorly Respond to Exercise Therapy in Heart Failure Patients With Reduced Ejection Fraction?
    Misumi, Kayo
    Arakawa, Tetsuo
    Nakanishi, Michio
    Nakao, Kazuhiro
    Hasegawa, Takuya
    Fukui, Shigefumi
    Yanase, Masanobu
    Noguchi, Teruo
    Anzai, Toshihisa
    Kusano, Kengo
    Yasuda, Satoshi
    Goto, Yoichi
    CIRCULATION, 2017, 136
  • [18] Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction
    Weaver, Fred A.
    Abraham, William T.
    Little, William C.
    Butter, Christian
    Ducharme, Anique
    Halbach, Marcel
    Klug, Didier
    Lovett, Eric G.
    Madershahian, Navid
    Muller-Ehmsen, Jochen
    Schafer, Jill E.
    Senni, Michele
    Swarup, Vijay
    Wachter, Rolf
    Zile, Michael R.
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2016, 28 (02) : 320 - 328
  • [19] Baroreflex activation therapy for heart failure with reduced ejection fraction: A comprehensive systematic review and meta-analysis
    Shi, Ruijie
    Sun, Tong
    Wang, Mengxi
    Xiang, Qian
    Ding, Yuhan
    Yin, Siyuan
    Chen, Yan
    Shen, Le
    Yu, Peng
    Chen, Xiaohu
    HELIYON, 2024, 10 (02)
  • [20] Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction
    Gronda, Edoardo
    Seravalle, Gino
    Trevano, Fosca Quarti
    Costantino, Giuseppe
    Casini, Andrea
    Alsheraei, Ali
    Lovett, Eric G.
    Vanoli, Emilio
    Mancia, Giuseppe
    Grassi, Guido
    JOURNAL OF HYPERTENSION, 2015, 33 (08) : 1704 - 1708